Loading…
← CockpitCompetitor Analysis › JSLL.NS Jeena Sikho Lifecare LimitedOpen in the cockpit ↗

Jeena Sikho Lifecare LimitedJSLL.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Medical/Nursing Services
Momentum laggard 0
Mkt cap
$394M
US dollars, full cap
Free float
28%
of shares outstanding
$/day
$3.25M
20-day average traded
Fwd P/E
17.4×
forward earnings
ROIC−WACC
+39.4 pp
WACC 12.6%
Hurdle
-35 pp
Req g minus delivered
Next earnings
82 days
8 Feb 2027
Close · INR₹296.35
1D-1.2%
1W-18.2%
1M-19.9%
3M-41.7%
6M-54.7%
YTD-56.5%
1Y-60.5%
ATR %7.0%
Beta1.17
52w lowhigh63.4% off high

What Jeena Sikho Lifecare does

Employees: 5,546

Jeena Sikho Lifecare at a glance

Size Jeena Sikho Lifecare (JSLL.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $394M, the 956th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹296.35 on 18 Nov 2026.

Performance Over six months the shares fell 54.7%, against -3.5% for the median peer and +3.8% for the India market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 135.3% over the last twelve months (peer median +5.1%); the operating margin is 31.6% (peer median 8.0%).

Valuation It trades at 17.4× forward earnings against a peer median of 17.1× (7th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +43%, so the hurdle is -35 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 39.4 points above its cost of capital (12.6% WACC).

Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 98JSLL.NS 46
Six months, rebased to 100: Jeena Sikho Lifecare against the median of its 20 peers (local-currency closes).

Jeena Sikho Lifecare financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹8.97B₹8.01B₹4.69B₹3.24B₹2.04B
Revenue growth—+71%+45%+59%—
Gross profit₹5.57B₹5.10B₹2.81B₹2.17B₹1.35B
EBITDA₹3.43B₹3.52B₹1.42B₹936M₹464M
Net income₹2.14B₹2.22B₹799M₹692M₹337M
Free cash flown/a₹2.21B₹452M₹238M-₹219M
Capital expendituren/a₹341M₹423M₹155M₹392M
Total debt₹1.68B₹1.27B₹1.17B₹5.39M₹8.08M

Quarterly statements and history in the cockpit →

Jeena Sikho Lifecare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%9860IDXACLM12AYUPASRTA127120300642NIOXAUNA301060DRAGARWQDNAWELLFLGTNEPHROPLUSGMRSJSLL.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Jeena Sikho Lifecare is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×9860IDXACLM12SRTANIOXAUNA3218WELLNEPHROPLUSGMRSJSLL.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jeena Sikho Lifecare is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%9860IDXACLM12AYUPA300642AUNA3218301060DRAGARWQWELLNEPHROPLUSGMRS1951JSLL.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jeena Sikho Lifecare is the large dot.

Jeena Sikho Lifecare competitors and peer comparison

How Jeena Sikho Lifecare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jeena Sikho Lifecare against its 20 peers (data as of 18 Nov 2026)
MeasureJSLL.NSPeer medianRank in peer set
1-month return-19.9%-6.8%5th lowest of 21
6-month return-54.7%-3.5%2nd lowest of 20
Distance from 52-week high-63.4%-26.3%2nd lowest of 21
Revenue growth (TTM)+135.3%+5.1%highest of 21
Operating margin31.6%8.0%highest of 21
Forward P/E17.4×17.1×7th cheapest of 13
Growth the price implies (Req g, 7 yrs)7.3%5.6%8th most demanding of 17
Growth delivered (Del g)+42.6%+15.4%2nd highest of 17
Hurdle (Req g minus delivered)-35.3 pp-10.9 pp2nd least demanding of 17
ROIC minus cost of capital+39.4 pp-2.5 pphighest of 20
EV / EBITDA10.4×8.8×6th most expensive of 13
Net debt / EBITDA-0.3×1.6×5th least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
M1 Kliniken M12.DEGermany$368M+1%-28%13%16.4×-5.3%+17.9%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%n/a-14.9%+9.6%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Tellgen 300642.SZChina$328M-11%+5%8%n/a18.8%-5.8%
Oncology Institute STLNUnited States$326Mn/a+35%-3%n/a5.4%+21.8%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%19.8×3.4%+15.3%
Auna AUNAUnited States$309M-5%+17%13%4.1×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%9.2×-13.8%+15.4%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%n/a19.6%+27.5%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%

Questions

Which companies are Jeena Sikho Lifecare's closest peers?
The cockpit's peer set: ADICON (9860.HK), Integral Diagnostics (IDX.AX), Australian Clinical Labs (ACL.AX), M1 Kliniken (M12.DE), Australian Unity Ltd Pref (AYUPA.AX), Strata Critical Medical (SRTA), JS Link (127120.KS), Tellgen (300642.SZ).
Is Jeena Sikho Lifecare expensive compared with its peers?
On forward p/e it trades at 17.4× against a peer median of 17.1×, 7th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +43%, so the hurdle is -35 pp: the price already allows for a slowdown.
How has Jeena Sikho Lifecare stock performed?
Over six months to 18 Nov 2026 the shares returned -54.7% against -3.5% for the median peer; over one year -60.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.